Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Rhythm Pharmaceuticals Inc (Rhythm Pharmaceuticals) is a biopharmaceutical company that focuses on developing precision medicines for rare neuroendocrine diseases. The company's lead product is IMCIVREE (setmelanotide), a medicine designed to treat hyperphagia and severe obesity caused by MC4R pathway diseases. Rhythm Pharmaceuticals clinical trials program includes Bivamelagon (LB54640), for acquired hypothalamic obesity; and RM-718, a new weekly MC4R–specific agonist designed to not cause hyperpigmentation. It also developing therapies for treatment of congenital hyperinsulinism (CHI). The company operate in Ireland, the US, the UK, the Netherland, Germany, France, Spain, Japan, Canada and Italy. Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
222 Berkeley Street, 12th Floor, Boston, Massachusetts, 02116
Website
rhythmtx.com
Telephone
1 857 2644280
No of Employees
414
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RYTM (NASD)
Revenue (2024)
$189.8M
45.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
24.6%
(2024 vs 2023)
Market Cap*
$6.0B
Net Profit Margin (2024)
XYZ
48.3%
(2024 vs 2023)
* As of and is in US$
Rhythm Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | IMCIVREE |
| IMCIVREE (Setmelanotide): Chronic Weight Management, Hyperphagia and Severe Obesity | Rhythm |
| Severe Obesity | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company received approval from Japan’s Ministry of Health, Labor and Welfare for IMCIVREE (setmelanotide) to treat patients living with acquired hypothalamic obesity. |
| 2026 | Regulatory Approval | In March, the company received approval from the U.S. FDA for IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity in adult and pediatric patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome or genetically confirmed pro-opiomelanocortin. |
| 2025 | Contracts/Agreements | In November, the company signed a Product Registration Agreement with Non-Insured Health Benefits for public reimbursement of IMCIVREE for weight management in eligible adult and pediatric patients. |
Competitor Comparison
| Key Parameters | Rhythm Pharmaceuticals Inc | Alnylam Pharmaceuticals Inc | BridgeBio Pharma Inc | Palatin Technologies Inc | Crinetics Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Cambridge | Palo Alto | Princeton | San Diego |
| State/Province | Massachusetts | Massachusetts | California | New Jersey | California |
| No. of Employees | 414 | 2,500 | 834 | 25 | 594 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David P. Meeker, M.D | Chief Executive Officer; President; Chairman | Executive Board | 2020 | 71 |
| Hunter C. Smith | Chief Financial Officer | Senior Management | 2017 | 58 |
| Manher Joshi | Chief Medical Officer | Senior Management | 2026 | - |
| Alastair Garfield | Chief Scientific Officer | Senior Management | 2024 | 46 |
| Alicia Fiscus | Senior Vice President; Head - Global Regulatory Affairs | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer